A practical reference on IGF-1: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-12-13. Anything still debated is marked as such rather than presented as settled.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
These synthetic opioids have increased length and depth of satiating any opiate cravings and generate very strong analgesic effects due to their long metabolic half-life and strong receptor affinity at the mu-opioid receptor sites. Therefore, they impart much of the satiating and anti-addictive effects of methadone by suppressing drug cravings. It was only in 1947 that the drug was given the generic name "methadone" by the Council on Pharmacy and Chemistry of the American Medical Association. Since the patent rights of the I.G. Farbenkonzern and Farbwerke Hoechst were no longer protected, each pharmaceutical company interested in the formula could buy the rights for the commercial production of methadone for just one dollar (MOLL 1990). Methadone was introduced into the United States in 1947 by Eli Lilly and Company as an analgesic under the trade name Dolophine. An urban myth later arose that Nazi leader Adolf Hitler ordered the manufacture of methadone or that the brand name 'Dolophine' was named after him, probably based on the similarity of "doloph" with "Adolph". (The pejorative term "adolphine" would appear in the early 1970s.) However, the name "Dolophine" was a contraction of "Dolo" from the Latin word dolor (pain), and finis, the Latin word for "end". Therefore, Dolophine literally means "pain end". Methadone was studied as a treatment for opioid addiction at the Addiction Research Center of the Narcotics Farm in Lexington, Kentucky in the 1950s, and by Rockefeller University physicians Robert Dole and Marie Nyswander in the 1960s in New York City.
=== Fertilizer === Hydrolyzing a protein improves the digestibility not only for animals, but also for soil microbes. As a result, it becomes useful as a fertilizer providing nitrogen and potentially also sulfur. Hydrolyzed keratin from chicken feather is the most common type, though other kinds of waste proteins (e.g. waste wool, waste fish) are also re-used this way. Hydrolyzed protein fertilizer is considered an organic fertilizer. It contains a high amount of available nitrogen, and unlike unhydrolyzed feather meal, tends to release the nitrogen quickly. It helps the growth of soil microbes and improves soil quality.
Prince George's County Public Schools (PGCPS) is a public school district that serves Prince George's County, Maryland. During the 2024–25 academic year, the district enrolled around 133,000 students and operated over 200 schools. PGCPS is the second-largest school district in Maryland, the third-largest district in the Washington-Baltimore metropolitan area, the 18th-largest in the United States, and the nation's largest school district with a majority-black student population. Headquartered in Upper Marlboro, PGCPS is the county's sole school district. The Prince George's County Board of Education comprises 14 members who oversee the Superintendent. On June 13, 2025, Dr. Shawn Joseph was named as interim Superintendent for the district. On June 1, 2026, the appointment of Dr. Joseph to the Superintendent role was made permanent.
The more recent advent of mobile phones and other gadgets that are worn on the waist has diminished the appeal of carrying an additional item in the same location, especially as such pocketable gadgets usually have timekeeping functionality themselves. In the US, a gift of a gold-cased pocket watch is traditionally awarded to an employee upon their retirement. The pocket watch has regained popularity with the steampunk subcultural movement embracing the arts and fashions of the Victorian era, during which pocket watches were nearly ubiquitous. In animated films and video games, especially within the fantasy genre, devices resembling pocket watches commonly represent objects with the ability to alter time, such as by time travel.
=== Low molecular weight P-type channel blockers === Low molecular weight channel blockers have advantages over peptide blockers in drug development. One advantage of low molecular weight channel blockers is that they can penetrate tissue, which is important for crossing the blood–brain barrier. There is no specific low molecular weight channel blocker for P-type channels. However, there are a number of these blocker compounds which can effect the activity of the P-type channels. These include:
Sources: en.wikipedia.org
Lurasidone, sold under the brand name Latuda among others, is an atypical antipsychotic medication used to treat schizophrenia and bipolar depression. It is taken by mouth. Common side effects include sedation, indigestion, nausea, and insomnia. At higher dosages, there is an increased risk for restlessness and movement problems. Serious side effects are valid for all atypical antipsychotics and may include the potentially permanent movement disorder tardive dyskinesia, as well as neuroleptic malignant syndrome, angioedema, and high blood sugar levels. Although lurasidone is less likely to cause high blood sugar levels in most patients, hyperosmolar hyperglycemic syndrome may occur. In older people with psychosis as a result of dementia, it may increase the risk of dying. Use during pregnancy is of unclear safety. Lurasidone was first approved for medical use in the United States in 2010, for treating schizophrenia. In 2013, it was approved in Canada and by the U.S. Food and Drug Administration (FDA) to treat bipolar depression, either as monotherapy or adjunctively with lithium or valproate. It is not FDA approved for treating manic symptoms associated with bipolar disorder despite its FDA approval for treating bipolar depression. Generic versions were approved in the United States in 2019, and became available in 2023. In 2021, it was the 193rd most commonly prescribed medication in the United States, with more than 2 million prescriptions.
=== 28 May === The Mayor of Kyiv, Vitali Klitschko, claimed that Russian drones attacked the Ukrainian capital. Two people were killed by falling drone debris, while a woman was injured. Two high-rise apartments were set on fire. The Ukrainian Air Force claimed that 58 out of 59 drones had been shot down, with more than 40 of them intercepted over Kyiv. Fires were reported in the Solomyanskyi, Holosiivskyi and Pecherskyi Districts. The attack came on the anniversary of Kyiv's founding in 482 AD. It was later described as Russia's largest drone attack on Kyiv since the war began. Air raid alerts were activated in 12 oblasts, from Volyn in the north-west to Dnipropetrovsk in the south-east. There were also reports of explosions in Zhytomyr, where at least 26 residential buildings were damaged as well as schools and medical units. Shelling was also reported in Sumy Oblast, which borders Russia, and in Nikopol, across the Dnipro River from the Zaporizhzhia Nuclear Power Plant. Russia said its air defences shot down several drones approaching the Ilsky oil refinery in Krasnodar Krai. The Ukrainian General Staff claimed that 80 Russian soldiers deserted their positions in Lysychansk, Luhansk Oblast, while 30 others deserted from Bakhmut. Valerii Zaluzhnyi, Commander-in-Chief of the Armed Forces of Ukraine, reported that all the preparations for the anticipated major counter-attack are complete and that they were only waiting for the decision to strike.
Medical Oncology, which involves treatment of cancer with chemicals, biological products and immunotherapy Radiation Oncology, or the careful use of high-energy radiation to treat cancer The goal of radiation therapy is to deliver a precisely measured dose to the cancerous tumor, while protecting normal tissue around the tumor Hematology, or the diagnosis and treatment of diseases of the blood and blood forming organs Genetic Testing, a type of medical test that identifies changes in chromosomes, genes, or proteins. Most of the time, testing is used to find changes that are associated with inherited disorders Clinical Trials, studies that evaluate the effectiveness of new drugs and strategies In addition to providing cancer care, SOMC also holds annual breast cancer awareness events (referred to as “pink outs” or by the name “Paint It Pink”) to coincide with October's designation as Breast Cancer Awareness Month. The events have received positive community feedback and helped raise money for the SOMC Breast Cancer Compassion Fund. The Breast Cancer Compassion Fund provides money to help support breast cancer patients with expenses such as utilities, medications, transportation and common necessities needed during cancer care. In 2012, Portsmouth Mayor David Malone declared October 20 “Paint It Pink Day.” That year's event also grew to include a 5k run/walk. SOMC has also worked to raise breast cancer awareness by creating a “Pink Glove Dance” YouTube video featuring local residents and hospital employees.
=== Recommended dietary intake === The WHO recommends that both adults and children reduce the intake of free sugars to less than 10% of total energy intake. "Free sugars" include monosaccharides and disaccharides added to foods, and sugars found in fruit juice and concentrates, as well as in honey and syrups. On 20 May 2016, the United States Food and Drug Administration announced changes to the Nutrition Facts panel displayed on all foods, to be effective by July 2018. New to the panel is a requirement to list "added sugars" by weight and as a percentage of Daily Value (DV). For vitamins and minerals, the intent of DVs is to indicate how much should be consumed. For added sugars, the guidance is that 100% DV should not be exceeded. 100% DV is defined as 50 grams. For a person consuming 2000 calories a day, 50 grams is equal to 200 calories and thus 10% of total calories – the same guidance as the WHO. To put this in context, most 12-US-fluid-ounce (355 ml) cans of soda contain 39 grams of sugar. In the United States, a government survey on food consumption in 2013–14 reported that, for men and women aged 20 and older, the average total sugar intakes – naturally occurring in foods and added – were, respectively, 125 and 99 grams per day. The American Heart Association recommends even lower daily consumption of added sugars: 36 grams for men and 25 grams for women.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.